Caricamento...
Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV
BACKGROUND: Lopinavir is a specific reversible inhibitor of the enzyme HIV protease with mean oral bioavailability of less than 20% due to extensive hepatic metabolism by cytochrome P450 3A4. The reported half-life of Lopinavir is 5-6 hours and the maximum recommended daily dose is 400 mg/day. All t...
Salvato in:
| Pubblicato in: | Curr HIV Res |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Bentham Science Publishers
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6416462/ https://ncbi.nlm.nih.gov/pubmed/30246641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570162X16666180924101650 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|